By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for L-Leucine
» See Plans and Pricing
What is the development status for investigational drug L-Leucine?
L-Leucine is an investigational drug.
There have been 27 clinical trials for L-Leucine.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2001.
The most common disease conditions in clinical trials are Neuroblastoma, Ganglioneuroblastoma, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are National Cancer Institute (NCI), Roswell Park Cancer Institute, and IntraBio Inc.
Summary for L-Leucine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,041 |
| WIPO Patent Applications | 2,905 |
| Japanese Patent Applications | 169 |
| Clinical Trial Progress | Phase 3 (2001-10-01) |
| Vendors | 94 |
Recent Clinical Trials for L-Leucine
| Title | Sponsor | Phase |
|---|---|---|
| Treatment With Dinutuximab in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma | National Cancer Institute (NCI) | Phase 2 |
| Treatment With Dinutuximab in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma | Children's Oncology Group | Phase 2 |
| Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for L-Leucine
Top disease conditions for L-Leucine
Top clinical trial sponsors for L-Leucine
US Patents for L-Leucine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
